Study of inflammatory markers in sputum positive patients of pulmonary tuberculosis and its response to anti-tubercular treatment

Mohd Yousoof Dar (New Delhi, India), Mohd Yousoof Dar, Balakrishnan Menon, Harsh Vardhan, Sarfaraz Jamal, Mohammad Noufal

Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Mohd Yousoof Dar (New Delhi, India), Mohd Yousoof Dar, Balakrishnan Menon, Harsh Vardhan, Sarfaraz Jamal, Mohammad Noufal. Study of inflammatory markers in sputum positive patients of pulmonary tuberculosis and its response to anti-tubercular treatment. Eur Respir J 2016; 48: Suppl. 60, 2702

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Biomarkers of systemic inflammatory response in patients with tuberculosis, combined with HIV infection
Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers
Year: 2016


Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis
Source: International Congress 2016 – Active and latent tuberculosis: biomarkers
Year: 2016


The change in serum Ca 19-9 levels according to treatment responses in pulmonary nontuberculous mycobacterial disease
Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology
Year: 2015


Risk factors and clinical outcomes of delayed smear conversion in smear positive pulmonary tuberculosis
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016

Combined collapse therapy in the treatment of cavitary pulmonary tuberculosis (CPTB)
Source: International Congress 2015 – Management of TB: a patient focus
Year: 2015

Markers of cellular immunity in the diagnosis of tuberculosis pleurisy
Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers
Year: 2016


Association of serum cytokines with pulmonary tuberculosis treatment outcomes
Source: International Congress 2014 – Tuberculosis: diagnosis
Year: 2014

Treatment of patients with extensive TB and concomitant bronchial lesions with some anti-TB drugs delivered via nebulizer
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Year: 2013


Efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in newly diagnosed pulmonary TB
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016


Outcomes of early interferon-gamma release assay (IGRA) testing in recent contacts of smear positive pulmonary tuberculosis (TB)
Source: Annual Congress 2013 –Immunological diagnosis of tuberculosis and latent tuberculosis infection
Year: 2013


Clinical evaluation of several biomarkers including IFN-γ for the diagnosis of tuberculosis infection
Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers
Year: 2016

Risk factors for active tuberculosis in patients with inflammatory bowel disease: A case-control study
Source: International Congress 2015 – Latent TB infection and screening
Year: 2015


Side effects of chemical preparations in patients with drug-resistant pulmonary tuberculosis
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015

Initiation of anti-TNF therapy within 3 weeks of LTBI treatment in patients with immune-mediated inflammatory diseases
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014

Lag period for diagnosing and starting treatment for pulmonary tuberculosis patients
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 2
Year: 2014


How long do patients with pulmonary tuberculosis remain smear and culture positive?
Source: Annual Congress 2013 –Tuberculosis: clinical epidemiology and public health
Year: 2013


Influence of modern basic therapy of bronchial asthma (BA) on the course of pulmonary TB in patients with pulmonary TB associated with BA
Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1
Year: 2014

Verification of pulmonary tuberculosis in HIV-infected patients with low CD4
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014

Diagnosing latent tuberculosis in immunocompromised patients measuring blood IP-10 production capacity: An analysis of chronic renal faulire patients
Source: International Congress 2015 – Screening strategies in TB
Year: 2015


The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016